VanEck Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

VanEck Associates’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,878	Closed	-$810K	–	1435
2023 Q2	$810K	Sell	7,878 -817	-9%	-$86.2K	﹤0.01%	915
2023 Q1	$949K	Sell	8,695 -6,767	-44%	-$748K	﹤0.01%	846
2022 Q4	$1.76M	Sell	15,462 -442	-3%	-$36.7K	﹤0.01%	699
2022 Q3	$984K	Buy	15,904 +4,636	+41%	+$324K	﹤0.01%	775
2022 Q2	$899K	Sell	11,268 -1,252	-10%	-$119K	﹤0.01%	810
2022 Q1	$1.32M	Buy	12,520 +1,308	+12%	+$127K	﹤0.01%	786
2021 Q4	$1.21M	Buy	11,212 +1,749	+18%	+$191K	﹤0.01%	813
2021 Q3	$1.04M	Buy	9,463 +2,029	+27%	+$211K	﹤0.01%	802
2021 Q2	$696K	Buy	7,434 +295	+4%	+$27.1K	﹤0.01%	862
2021 Q1	$657K	Buy	+7,139	New	+$602K	﹤0.01%	810

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VanEck Associates's HZNP Position: Q3 2023 in Review

VanEck Associates sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 7,878 shares — an estimated $810K sold.

VanEck Associates first reported a position in HZNP in Q1 2021 and held it in 10 quarters. The position peaked at $1.76M in Q4 2022. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

VanEck Associates reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
VanEck Associates sold 7,878 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $810K.
VanEck Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 10 quarters.
VanEck Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.76M in Q4 2022.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on VanEck Associates's 13F filing for Q3 2023, filed 8 Nov 2023.